A Keystone Gut Bacterium Christensenella minuta-A Potential Biotherapeutic Agent for Obesity and Associated Metabolic Diseases

被引：22

作者：

Ang, Wei-Shan ^{[1
]}

Law, Jodi Woan-Fei ^{[1
,2
]}

Letchumanan, Vengadesh ^{[1
,3
]}

Hong, Kar Wai ^{[1
]}

Wong, Sunny Hei ^{[4
]}

Ab Mutalib, Nurul Syakima ^{[1
,5
]}

Chan, Kok-Gan ^{[1
,6
,7
]}

Lee, Learn-Han ^{[1
]}

Tan, Loh Teng-Hern ^{[1
,8
]}

机构：

[1] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Novel Bacteria & Drug Discovery Res Grp NBDD, Microbiome & Bioresource Res Strength MBRS, Bandar Sunway 47500, Malaysia

[2] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Next Generat Precis Med & Therapeut Res Grp NMeT, Bandar Sunway 47500, Malaysia

[3] Monash Univ Malaysia, Jeffrey Cheah Sch Med & Hlth Sci, Pathogen Resistome Virulome & Diagnost Res Grp Pat, Bandar Sunway 47500, Malaysia

[4] Nanyang Technol Univ, Lee Kong Chian Sch Med, Singapore 308232, Singapore

[5] Univ Kebangsaan Malaysia, UKM Med Mol Biol Inst UMBI, Kuala Lumpur 56000, Malaysia

[6] Jiangsu Univ, Int Genome Ctr, Zhenjiang 212013, Peoples R China

[7] Univ Malaya, Inst Biol Sci, Fac Sci, Kuala Lumpur 50603, Malaysia

[8] Monash Univ Malaysia, Clin Sch Johor Bahru, Jeffrey Cheah Sch Med & Hlth Sci, Innovat Bioprospect Dev Res Grp InBioD, Johor Baharu 80100, Malaysia

来源：

FOODS | 2023年 / 12卷 / 13期

关键词：

Christensenella minuta; next-generation probiotic; metabolic diseases; obesity; inflammatory bowel disease; FECAL MICROBIOTA TRANSPLANTATION; PROBIOTICS; WEIGHT; ACIDS;

D O I：

10.3390/foods12132485

中图分类号：

TS2 [食品工业];

学科分类号：

0832 ;

摘要：

A new next-generation probiotic, Christensenella minuta was first discovered in 2012 from healthy human stool and described under the phylum Firmicutes. C. minuta is a subdominant commensal bacterium with highly heritable properties that exhibits mutual interactions with other heritable microbiomes, and its relative abundance is positively correlated with the lean host phenotype associated with a low BMI index. It has been the subject of numerous studies, owing to its potential health benefits. This article reviews the evidence from various studies of C. minuta interventions using animal models for managing metabolic diseases, such as obesity, inflammatory bowel disease, and type 2 diabetes, characterized by gut microbiota dysbiosis and disruption of host metabolism. Notably, more studies have presented the complex interaction between C. minuta and host metabolism when it comes to metabolic health. Therefore, C. minuta could be a potential candidate for innovative microbiome-based biotherapy via fecal microbiota transplantation or oral administration. However, the detailed underlying mechanism of action requires further investigation.

引用

页数：14

共 82 条

[1] The interaction between the gut Microbiota and herbal medicines [J].